Related Experiment Video
Updated: Jan 2, 2026
Minimally Invasive Cisterna Magna Injection Model for Leptomeningeal Metastasis Studies in Mice
Published on: May 23, 2025
Management of CNS metastases in patients with EGFR mutation-positive NSCLC
1Department of Medical Oncology, K.S. Hegde Medical Academy, Mangalore, Karnataka, India.
Abstract:
Central nervous system (CNS) metastases are a frequent and severe complication associated with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC). The first- and second-generation EGFR tyrosine kinase inhibitors (TKIs) have shown considerable efficacy in EGFR-mutated NSCLC. However, their limited potential to cross the blood-brain barrier (BBB) renders them less effective in the management of CNS metastases in NSCLC. Osimertinib, a third-generation irreversible EGFR-TKI with good potential to cross the BBB, has shown significant clinical activity and acceptable safety profile in patients with EGFR-positive NSCLC brain and leptomeningeal metastases. The progression-free survival (PFS) of up to 15.2 months in CNS metastases patients in the FLAURA trial and the CNS objective response rates (ORRs) of 54% and 43% in the AURA/AURA2 and BLOOM trials, respectively, have established the role of osimertinib in patients with NSCLC with CNS metastases. The AURA3 trial also reported a PFS of 8.5 months and overall ORR of 71%. These data have supported osimertinib to be recognized as a "preferred" first-line treatment for EGFR-positive metastatic NSCLC by the National Comprehensive Cancer Network (NCCN). With limited treatment options available, upfront administration of osimertinib in patients with NSCLC irrespective of EGFR T790M and CNS metastases may improve the overall response rate and potentially reduce the adverse effects of radiotherapy. Our review focuses on the management of EGFR-mutated NSCLC CNS metastases in the context of recent NCCN guidelines.
Insights
Osimertinib effectively treats brain metastases in non-small cell lung cancer (NSCLC) with EGFR mutations, offering improved progression-free survival and response rates compared to older treatments. This makes it a preferred first-line option for EGFR-mutated NSCLC with CNS involvement.
Area of Science:
- Oncology
- Medical Research
- Pharmacology
Background:
- Central nervous system (CNS) metastases are a significant challenge in EGFR-mutated non-small cell lung cancer (NSCLC).
- First- and second-generation EGFR tyrosine kinase inhibitors (TKIs) have limited efficacy against CNS metastases due to poor blood-brain barrier (BBB) penetration.
- Limited treatment options exist for NSCLC patients with brain and leptomeningeal metastases.
Purpose of the Study:
- To review the efficacy and safety of osimertinib in managing CNS metastases in EGFR-mutated NSCLC.
- To highlight the role of osimertinib as a first-line treatment option based on recent clinical trial data and NCCN guidelines.
- To discuss the potential benefits of upfront osimertinib administration for NSCLC patients with CNS metastases.
Main Methods:
- Review of clinical trial data (FLAURA, AURA/AURA2, BLOOM, AURA3) evaluating osimertinib in NSCLC with CNS metastases.
- Analysis of progression-free survival (PFS) and objective response rates (ORRs) in relevant patient populations.
- Consideration of National Comprehensive Cancer Network (NCCN) guidelines regarding first-line treatment for EGFR-mutated NSCLC.
Main Results:
- Osimertinib demonstrates significant clinical activity in EGFR-positive NSCLC patients with brain and leptomeningeal metastases.
- PFS of up to 15.2 months and CNS ORRs of 54% (AURA/AURA2) and 43% (BLOOM) were observed.
- AURA3 trial reported a PFS of 8.5 months and an overall ORR of 71% with osimertinib.
- Osimertinib has good BBB penetration, enhancing its effectiveness against CNS disease.
Conclusions:
- Osimertinib is an effective and well-tolerated treatment for EGFR-mutated NSCLC with CNS metastases.
- Clinical trial data support osimertinib's role in improving outcomes for patients with brain metastases.
- NCCN guidelines recognize osimertinib as a preferred first-line treatment for EGFR-mutated metastatic NSCLC, including cases with CNS involvement.
